Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
The DOI matches its Crossref record; 131 of the 134 references it cites were found in a registry or an index.
Abstract
Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are identified as safe, well-tolerated rapid-acting antidepressants in adults with treatment-resistant depression, and also mitigate measures of suicidality. Psilocybin is a naturally occurring psychoactive alkaloid and non-selective agonist at many serotonin receptors, especially at serotonin 5-HT 2A receptors, and is found in the Psilocybe genus of mushrooms. Preliminary studies with psilocybin have shown therapeutic promise across diverse populations including major depressive disorder. The pharmacodynamic mechanisms mediating the antidepressant and psychedelic effects of psilocybin are currently unknown but are thought to involve the modulation of the serotonergic system, primarily through agonism at the 5-HT 2A receptors and downstream changes in gene expression. It is also established that indirect effects on dopaminergic and glutamatergic systems are contributory, as well as effects at other lower affinity targets. Along with the direct effects on neurochemical systems, psilocybin alters neural circuitry and key brain regions previously implicated in depression, including the default mode network and amygdala. The aim of this review is to synthesize the current understanding of the receptor pharmacology and neuronal mechanisms underlying the psychedelic and putative antidepressant properties of psiloc…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite neuroplasticity phenomena mainly occurring in the prefrontal cortex, amygdala, and hippocampus, 66”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [66]
In the citing paper
“Psilocybin (4-phosphryloxy-N,N-dimethyltryptamine) is a serotonergic classic psychedelic (19–25) that has been examined in combination with psychological support as a promising treatment option in clinical trials for various disorders (26–28).”
In the citing paper
“As with SSRIs, their enhancement of serotonergic transmission is likely relevant to their antidepressant effects through downstream changes in gene expression, indirect effects on glutamatergic and dopaminergic systems, and changes in emotional and cognitive brain networks, summarized in recent reviews [128, 129].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [129]
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 1×
“Psilocybin is a naturally occurring psychedelic found in the Psilocybe genus of mushrooms [30].”
BackgroundHippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor.
Korte, M., Carroll, P., Wolf, E., Brem, G., Thoenen, H., & Bonhoeffer, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8856 · Cited by 1,426
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391 · cited 1×
“, analyses of secondary outcomes were not corrected for multiple comparisons), the relative antidepressant efficacy of psilocybin remains incompletely understood [32].”
ResultPatterson, S. L., Abel, T., Deuel, T. A. S., Martin, K. C., Rose, J. C., & Kandel, E. R. (1996) · Neuron · doi:10.1016/s0896-6273(00)80140-3 · Cited by 1,233
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · cited 2×
“In vitro and in vivo studies have also demonstrated increased neuritogenesis and spinogenesis in the PFC upon 5-HT2AR agonism [100].”
BackgroundNeural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 1×
“Ultimately, complex alterations in connectivity between neural networks occur, allowing new connections in the brain to be formed; this phenomenon has been referred to as a ‘pharmaco-physiological interaction’ [93].”
Background
Cited by
Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study
Peck, S. K., Shao, S., Gruen, T., Yang, K. H., Babakanian, A., Trim, J., Finn, D. M., & Kaye, W. H. (2023) · Nature Medicine · doi:10.1038/s41591-023-02455-9 · Cited by 184
New and emerging approaches to treat psychiatric disorders
Scangos, K. W., State, M. W., Miller, A. H., Baker, J. T., & Williams, L. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02197-0 · Cited by 179
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
Haikazian, S., Chen-Li, D. C. J., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115531 · Cited by 134
Self-citationTherapeutic use of psilocybin: Practical considerations for dosing and administration
MacCallum, C. A., Lo, L. A., Pistawka, C. A., & Deol, J. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1040217 · Cited by 128
“5-HT2A receptors are also highly expressed in the visual cortex, contributing to the visual hallucinations associated with psilocin (27, 32).”
BackgroundEfficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Metaxa, A.-M., & Clarke, M. J. (2024) · BMJ · doi:10.1136/bmj-2023-078084 · Cited by 120
Metadata
- Authors
- Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., Lin, K., Ho, R., Rosenblat, J. D., Castle, D., & McIntyre, R. S.
- Affiliations
- University Health Network (CA)
- Guangzhou Medical University (CN)
- National University of Singapore (SG)
- Centre for Addiction and Mental Health (CA)
- Corresponding author
- McIntyre, Roger S.
- ORCID
- Venue
- CNS Drugs
- Published
- 2021-11-17
- Volume
- 36
- Issue
- 1
- Pages
- 17-30
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W3213007658
- Cited by
- 127
- References
- 134
- Citations by year
- 2026: 25 · 2025: 30 · 2024: 28 · 2023: 34 · 2022: 10
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psilocybin, depression, rapid-acting antidepressants, treatment-resistant depression, 5-HT2A receptor, serotonergic system, ketamine, esketamine, default mode network, amygdala, dopaminergic system, glutamatergic system, gene expression, receptor pharmacology
- MeSH terms
- Antidepressive Agents, Brain, Major Depressive Disorder, Depressive Disorder, Major, Humans, Psilocybin, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. https://app.cochat.ai/papers/10.1007/s40263-021-00877-y
- The paper
- Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., Lin, K., Ho, R., Rosenblat, J. D., Castle, D., & McIntyre, R. S. (2022). Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs. https://doi.org/10.1007/s40263-021-00877-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.